{"id":2284,"date":"2023-12-26T17:13:45","date_gmt":"2023-12-26T16:13:45","guid":{"rendered":"https:\/\/neurocirugialmeria.com\/?p=2284"},"modified":"2023-12-26T17:21:12","modified_gmt":"2023-12-26T16:21:12","slug":"gantenerumab-en-el-tratamiento-de-la-enfermedad-de-alzheimer-en-estadios-precoes-resultados-de-un-ensayo-clinico","status":"publish","type":"post","link":"https:\/\/neurocirugialmeria.com\/en\/2023\/12\/26\/gantenerumab-en-el-tratamiento-de-la-enfermedad-de-alzheimer-en-estadios-precoes-resultados-de-un-ensayo-clinico\/","title":{"rendered":"Gantenerumab en el tratamiento de la enfermedad de Alzheimer en estadios precoces: resultados de un ensayo cl\u00ednico"},"content":{"rendered":"

La revista New England Journal of Medicine<\/a> ha publicado recientemente los resultados de un ensayo cl\u00ednico destinados a evaluar la capacidad de una nueva mol\u00e9cula, Gantenerumab, par detener la progresi\u00f3n de la enfermedad de Alzheimer.<\/p>\n\n\n\n

El Gantenerumab es un nuevo anticuerpo monoclonal que, de id\u00e9ntica manera que otros ya desarrollados, tiene capacidad para adherirse y eliminar las mol\u00e9culas de amiloide cuyo dep\u00f3sito a nivel cerebral se relaciona con la aparici\u00f3n y el avance de esta enfermedad.<\/p>\n\n\n\n

El trabajo cont\u00f3 con casi 2000 participantes entre los que se diferenciaron pacientes con enfermedad de Alzheimer en estadio inicial y pacientes con deterioro cognitivo leve que a\u00fan no cumpl\u00edan los criterios de demencia. El resultado principal a evaluar fue la evoluci\u00f3n de la demencia determinada por la escala CDR al cabo de 2 a\u00f1os tras recibir el tratamiento.<\/p>\n\n\n\n

Los autores observaron c\u00f3mo pese a una reducci\u00f3n significativa del dep\u00f3stio de amiloide mediable mediante PET-TAC y punci\u00f3n lumbar, esto no se acompa\u00f1aba de un beneficio cl\u00ednicamente significativo en los pacientes del grupo de tratamiento frente al grupo control.<\/p>\n\n\n\n

Fuente: <\/strong>Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Two Phase 3 Trials of Gantenerumab in Early Alzheimer’s Disease. N Engl J Med. 2023 Nov 16;389(20):1862-1876.<\/a><\/p>","protected":false},"excerpt":{"rendered":"

La revista New England Journal of Medicine ha publicado recientemente los resultados de un ensayo cl\u00ednico destinados a evaluar la capacidad de una nueva mol\u00e9cula, Gantenerumab, par detener la progresi\u00f3n de la enfermedad de Alzheimer. El Gantenerumab es un nuevo anticuerpo monoclonal que, de id\u00e9ntica manera que otros ya desarrollados, tiene capacidad para adherirse y…<\/p>","protected":false},"author":183523340,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_seo_schema_type":"","_kadence_starter_templates_imported_post":false,"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_wpcom_ai_launchpad_first_post":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"{title}\n\n{excerpt}\n\n{url}","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"_wpas_customize_per_network":false,"jetpack_post_was_ever_published":false},"categories":[1771],"tags":[],"class_list":["post-2284","post","type-post","status-publish","format-standard","hentry","category-sin-categoria"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_likes_enabled":true,"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pbS7CP-AQ","jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/neurocirugialmeria.com\/en\/wp-json\/wp\/v2\/posts\/2284","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neurocirugialmeria.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/neurocirugialmeria.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/neurocirugialmeria.com\/en\/wp-json\/wp\/v2\/users\/183523340"}],"replies":[{"embeddable":true,"href":"https:\/\/neurocirugialmeria.com\/en\/wp-json\/wp\/v2\/comments?post=2284"}],"version-history":[{"count":3,"href":"https:\/\/neurocirugialmeria.com\/en\/wp-json\/wp\/v2\/posts\/2284\/revisions"}],"predecessor-version":[{"id":2289,"href":"https:\/\/neurocirugialmeria.com\/en\/wp-json\/wp\/v2\/posts\/2284\/revisions\/2289"}],"wp:attachment":[{"href":"https:\/\/neurocirugialmeria.com\/en\/wp-json\/wp\/v2\/media?parent=2284"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neurocirugialmeria.com\/en\/wp-json\/wp\/v2\/categories?post=2284"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/neurocirugialmeria.com\/en\/wp-json\/wp\/v2\/tags?post=2284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}